Isolated mammalian dendritic cell genes; related reagents

Abstract

Nucleic acids encoding various dendritic cell specific proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

What is claimed is:  
     
         1 . A composition of matter selected from the group consisting of: 
 a) a substantially pure or recombinant A05F12 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 2 or 4;    b) a natural sequence A05F12 comprising SEQ ID NO: 2 or 4;    c) a fusion protein comprising A05F12 sequence;    d) a substantially pure or recombinant A07C03 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 6, 8, or 10;    e) a natural sequence A07C03 comprising SEQ ID NO: 6, 8, or 10;    f) a fusion protein comprising A07C03 sequence;    g) a substantially pure or recombinant E02B02 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 12;    h) a natural sequence E02B02 comprising SEQ ID NO: 12; and    i) a fusion protein comprising E02B02 sequence.    
     
     
         2 . A substantially pure or isolated protein comprising a segment exhibiting sequence identity to a corresponding portion of an: 
 a) A05F12 of  claim 1 , wherein: 
 i) said homology is at least about 90% identity and said portion is at least about 9 amino acids;  
 ii) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or  
 iii) said homology is at least about 70% identity and said portion is at least about 25 amino acids;  
   b) A07C03 of  claim 1 , wherein: 
 i) said homology is at least about 90% identity and said portion is at least about 9 amino acids;  
 ii) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or  
 iii) said homology is at least about 70% identity and said portion is at least about 25 amino acids; or  
   c) E02B02 of  claim 1 , wherein: 
 i) said homology is at least about 90% identity and said portion is at least about 9 amino acids;  
 ii) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or  
 iii) said homology is at least about 70% identity and said portion is at least about 25 amino acids.  
   
     
     
         3 . The composition of matter of  claim 1 , wherein said: 
 a) A05F12 comprises a mature sequence of Table 1;    b) A05F12 protein or peptide: 
 i) is from a warm blooded animal selected from a primate or rodent, such as a human or mouse;  
 ii) comprises at least one polypeptide segment of SEQ ID NO: 2 or 4;  
 iii) exhibits a plurality of portions exhibiting said identity;  
 iv) is a natural allelic variant of a primate or rodent A05F12;  
 v) has a length at least about 30 amino acids;  
 vi) exhibits at least two non-overlapping epitopes which are specific for a primate or rodent A05F12;  
 vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate or rodent A05F12;  
 viii) has a molecular weight of at least 100 kD with natural glycosylation;  
 ix) is a synthetic polypeptide;  
 x) is attached to a solid substrate;  
 xi) is conjugated to another chemical moiety;  
 xii) is a 5-fold or less substitution from natural sequence; or  
 xiii) is a deletion or insertion variant from a natural sequence;  
   c) A07C03 comprises a mature sequence of Table 2;    d) A07C03 protein or peptide: 
 i) is from a warm blooded animal selected from a primate or rodent, such as a human or mouse;  
 ii) comprises at least one polypeptide segment of SEQ ID NO: 8 or 10;  
 iii) exhibits a plurality of portions exhibiting said identity;  
 iv) is a natural allelic variant of a primate or rodent A07C03;  
 v) has a length at least about 30 amino acids;  
 vi) exhibits at least two non-overlapping epitopes which are specific for a primate or rodent A07C03;  
 vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate or rodent A07C03;  
 viii) has a molecular weight of at least 100 kD with natural glycosylation;  
 ix) is a synthetic polypeptide;  
 x) is attached to a solid substrate;  
 xi) is conjugated to another chemical moiety;  
 xii) is a 5-fold or less substitution from natural sequence; or  
 xiii) is a deletion or insertion variant from a natural sequence;  
   e) E02B02 comprises a mature sequence of Table 3; or    f) E02B02 protein or peptide: 
 i) is from a warm blooded animal selected from a primate, such as a human;  
 ii) comprises at least one polypeptide segment of SEQ ID NO: 12;  
 iii) exhibits a plurality of portions exhibiting said identity;  
 iv) is a natural allelic variant of a primate E02B02;  
 v) has a length at least about 30 amino acids;  
 vi) exhibits at least two non-overlapping epitopes which are specific for a primate E02B02;  
 vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate oE02B02;  
 viii) has a molecular weight of at least 100 kD with natural glycosylation;  
 ix) is a synthetic polypeptide;  
 x) is attached to a solid substrate;  
 xi) is conjugated to another chemical moiety;  
 xii) is a 5-fold or less substitution from natural sequence; or  
 xiii) is a deletion or insertion variant from a natural sequence.  
   
     
     
         4 . A composition comprising: 
 a) a sterile A05F12 protein or peptide of  claim 1;     b) said A05F12 protein or peptide of  claim 1  and a carrier, wherein said carrier is: 
 i) an aqueous compound, including water, saline, and/or buffer; and/or  
 ii) formulated for oral, rectal, nasal, topical, or parenteral administration;  
   c) a sterile A07C03 protein or peptide of  claim 1;     d) said A07C03 protein or peptide of  claim 1  and a carrier, wherein said carrier is: 
 i) an aqueous compound, including water, saline, and/or buffer; and/or  
 ii) formulated for oral, rectal, nasal, topical, or parenteral administration;  
   e) a sterile E02B02 protein or peptide of  claim 1;  or    f) said E02B02 protein or peptide of  claim 1  and a carrier, wherein said carrier is: 
 i) an aqueous compound, including water, saline, and/or buffer; and/or  
 ii) formulated for oral, rectal, nasal, topical, or parenteral administration.  
   
     
     
         5 . The fusion protein of  claim 1 , comprising: 
 a) mature protein sequence of Table 1, 2, or 3;    b) a detection or purification tag, including a FLAG, His6, or Ig sequence; or    c) sequence of another receptor protein.    
     
     
         6 . A kit comprising a protein or polypeptide of  claim 1 , and: 
 a) a compartment comprising said protein or polypeptide; and/or    b) instructions for use or disposal of reagents in said kit.    
     
     
         7 . A binding compound comprising an antigen binding site from an antibody, which specifically binds to a natural: 
 A) A05F12 protein of  claim 1 , wherein: 
 a) said protein is a primate or rodent protein;  
 b) said binding compound is an Fv, Fab, or Fab2 fragment;  
 c) said binding compound is conjugated to another chemical moiety; or  
 d) said antibody: 
 i) is raised against a peptide sequence of a mature polypeptide of Table 1;  
 ii) is raised against a mature primate or rodent A05F12;  
 iii) is raised to a purified human A05F12;  
 iv) is raised to a purified mouse A05F12;  
 v) is immunoselected;  
 vi) is a polyclonal antibody;  
 vii) binds to a denatured A05F12;  
 viii) exhibits a Kd to antigen of at least 30 μM;  
 ix) is attached to a solid substrate, including a bead or plastic membrane;  
 x) is in a sterile composition; or  
 xi) is deteccably labeled, including a radioactive or fluorescent label;  
 
   B) A07C03 protein of  claim 1 , wherein: 
 a) said protein is a primate or rodent protein;  
 b) said binding compound is an Fv, Fab, or Fab2 fragment;  
 c) said binding compound is conjugated to another chemical moiety; or  
 d) said antibody: 
 i) is raised against a peptide sequence of a mature polypeptide of Table 2;  
 ii) is raised against a mature primate or rodent A07C03;  
 iii) is raised to a purified human A07C03;  
 iv) is raised to a purified mouse A07C03;  
 v) is immunoselected;  
 vi) is a polyclonal antibody;  
 vii) binds to a denatured A07C03;  
 viii) exhibits a Kd to antigen of at least 30 μM;  
 ix) is attached to a solid substrate, including a bead or plastic membrane;  
 x) is in a sterile composition; or  
 xi) is detectably labeled, including a radioactive or fluorescent label; or  
 
   C) E02B02 protein of  claim 1 , wherein: 
 a) said protein is a primate protein;  
 b) said binding compound is an Fv, Fab, or Fab2 fragment;  
 c) said binding compound is conjugated to another chemical moiety; or  
 d) said antibody: 
 i) is raised against a peptide sequence of a mature polypeptide of Table 3;  
 ii) is raised against a mature primate E02B02;  
 iii) is raised to a purified human E02B02;  
 iv) is immunoselected;  
 v) is a polyclonal antibody;  
 vi) binds to a denatured E02B02;  
 vii) exhibits a Kd to antigen of at least 30 μM;  
 viii) is attached to a solid substrate, including a bead or plastic membrane;  
 ix) is in a sterile composition; or  
 x) is detectably labeled, including a radioactive or fluorescent label  
 
   
     
     
         8 . A kit comprising said binding compound of  claim 7 , and: 
 a) a compartment comprising said binding compound; and/or    b) instructions for use or disposal of reagents in said kit.    
     
     
         9 . The kit of  claim 8  capable of making a qualitative or quantitative analysis.  
     
     
         10 . A composition comprising: 
 a) a sterile binding compound of  claim 7;  or    b) said binding compound of  claim 7  and a carrier, wherein said carrier is: 
 i) an aqueous compound, including water, saline, and/or buffer; and/or  
 ii) formulated for oral, rectal, nasal, topical, or parenteral administration.  
   
     
     
         11 . An isolated or recombinant nucleic acid encoding a protein or peptide or fusion protein of  claim 1 , wherein: 
 a) said A05F12 protein or peptide is from a mammal, including a primate or rodent;    b) said nucleic acid: 
 i) encodes an antigenic peptide sequence of Table 1;  
 ii) encodes a plurality of antigenic peptide sequences of Table 1;  
 iii) exhibits at least about 80% identity to a natural cDNA encoding said segment;  
 iv) is an expression vector;  
 v) further comprises an origin of replication;  
 vi) is from a natural source;  
 vii) comprises a detectable label;  
 viii) comprises synthetic nucleotide sequence;  
 ix) is less than 6 kb, preferably less than 3 kb;  
 x) is from a mammal, including a primate or rodent;  
 xi) comprises a natural full length coding sequence;  
 xii) is a hybridization probe for a gene encoding said A05F12; or  
 xiii) is a PCR primer, PCR product, or mutagenesis primer;  
   c) said A05C03 is from a mammal, including a primate or rodent;    d) said nucleic acid: 
 i) encodes an antigenic peptide sequence of Table 2;  
 ii) encodes a plurality of antigenic peptide sequences of Table 2;  
 iii) exhibits at least about 80% identity to a natural cDNA encoding said segment;  
 iv) is an expression vector;  
 v) further comprises an origin of replication;  
 vi) is from a natural source;  
 vii) comprises a detectable label;  
 viii) comprises synthetic nucleotide sequence;  
 ix) is less than 6 kb, preferably less than 3 kb;  
 x) is from a mammal, including a primate or rodent;  
 xi) comprises a natural full length coding sequence;  
 xii) is a hybridization probe for a gene encoding said A07C03; or  
 xiii) is a PCR primer, PCR product, or mutagenesis primer;  
   e) said E02B02 is from a mammal, including a primate; or    f) said nucleic acid: 
 i) encodes an antigenic peptide sequence of Table 3;  
 ii) encodes a plurality of antigenic peptide sequences of Table 3;  
 iii) exhibits at least about 80% identity to a natural cDNA encoding said segment;  
 iv) is an expression vector;  
 v) further comprises an origin of replication;  
 vi) is from a natural source;  
 vii) comprises a detectable label;  
   
     
     
         15 . The kit of claim  14  capable of making a qualitative or quantitative analysis.  
     
     
         16 . A nucleic acid which: 
 a) hybridizes under wash conditions of 30° C. and less than 2M salt to SEQ ID NO: 1 or 3;    b) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate or rodent A05F12;    c) hybridizes under wash conditions of 30° C. and less than 2M salt to SEQ ID NO: 5, 7, or 9;    d) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate or rodent A07C03;    e) hybridizes under wash conditions of 30° C. and less than 2M salt to SEQ ID NO: 11; or    b) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate E02B02.    
     
     
         17 . The nucleic acid of  claim 16 , wherein: 
 a) said wash conditions are at 45° C. and/or 500 mM salt; or    b) said identity is at least 90% and/or said stretch is at least 55 nucleotides.    
     
     
         18 . The nucleic acid of  claim 17 , wherein: 
 a) said wash conditions are at 55° C. and/or 150 mM salt; or    b) said identity is at least 95% and/or said stretch is at least 75 nucleotides.    
     
     
         19 . A method of modulating physiology or development of a cell or tissue culture cells comprising contacting said cell with: 
 a) a binding composition of  claim 7 , which binds to a primate or rodent A05F12;    b) a binding composition of  claim 7 , which binds to a primate or rodent A07C03;    c) a binding composition of  claim 7 , which binds to a primate E01B02;    d) a antisense nucleic acid which blocks expression of a primate or rodent A05F12;    e) a antisense nucleic acid which blocks expression of a primate or rodent A07C03; or    f) a antisense nucleic acid which blocks expression of a primate E02B02.